About
Eradivir develops small molecule therapies using its Bispecific Antigenic immuno-Therapy (BAiT™️) technology to target and flag diseased cells and viruses, enabling immune system clearance, with a focus on treating viral infections such as influenza.
Explore Eradivir's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.